| 1401 |
Apheresis |
Allogeneic |
Myelodysplasia |
Hematology |
2025 |
Standard Therapy |
Germany |
47 |
| 1402 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
58 |
| 1403 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
76 |
| 1404 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
USA |
55 |
| 1405 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
70 |
| 1406 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
55 |
| 1407 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Czechia |
51 |
| 1408 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
56 |
| 1409 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
Italy |
62 |
| 1410 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
Norway |
59 |
| 1411 |
Apheresis |
Allogeneic |
Myeloid Sarcoma |
Hematology |
2025 |
Standard Therapy |
Ukraine |
24 |
| 1412 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
NETHERLANDS |
63 |
| 1413 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
58 |
| 1414 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
55 |
| 1415 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Poland |
68 |
| 1416 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
71 |
| 1417 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Sweden |
62 |
| 1418 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
5 |
| 1419 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Turkey |
2 |
| 1420 |
Apheresis |
Allogeneic |
Hodgkin's Lymphoma (HL) |
Hematology |
2025 |
Standard Therapy |
South Africa |
38 |
| 1421 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
Poland |
60 |
| 1422 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
72 |
| 1423 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
59 |
| 1424 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
NETHERLANDS |
72 |
| 1425 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
74 |
| 1426 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
72 |
| 1427 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
19 |
| 1428 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Canada |
62 |
| 1429 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Switzerland |
25 |
| 1430 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
69 |
| 1431 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
64 |
| 1432 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Lithuania |
55 |
| 1433 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Greece |
42 |
| 1434 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
55 |
| 1435 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
49 |
| 1436 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Poland |
63 |
| 1437 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Portugal |
68 |
| 1438 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
41 |
| 1439 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
64 |
| 1440 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
68 |
| 1441 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
61 |
| 1442 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
73 |
| 1443 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Ukraine |
39 |
| 1444 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
73 |
| 1445 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Russian Federation |
57 |
| 1446 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
BELARUS |
22 |
| 1447 |
Apheresis |
Allogeneic |
Other Leukemia |
Hematology |
2025 |
Standard Therapy |
Belgium |
60 |
| 1448 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
48 |
| 1449 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Italy |
20 |
| 1450 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
Lithuania |
51 |
| 1451 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
71 |
| 1452 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Denmark |
72 |
| 1453 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
USA |
56 |
| 1454 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
63 |
| 1455 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
68 |
| 1456 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
53 |
| 1457 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
70 |
| 1458 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Poland |
14 |
| 1459 |
Apheresis |
Allogeneic |
NHL Non-Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
USA |
57 |
| 1460 |
Apheresis |
Allogeneic |
NHL Non-Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
Poland |
49 |
| 1461 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Russian Federation |
43 |
| 1462 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
76 |
| 1463 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
Belgium |
63 |
| 1464 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
63 |
| 1465 |
Apheresis |
Allogeneic |
Other Leukemia, Specify, CNL |
Hematology |
2025 |
Standard Therapy |
USA |
70 |
| 1466 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
53 |
| 1467 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Iran |
8 |
| 1468 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
21 |
| 1469 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Denmark |
65 |
| 1470 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Romania |
25 |
| 1471 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Italy |
27 |
| 1472 |
Apheresis |
Allogeneic |
Polycythaemia Vera |
Hematology |
2025 |
Standard Therapy |
Germany |
61 |
| 1473 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
25 |
| 1474 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
51 |
| 1475 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
70 |
| 1476 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
53 |
| 1477 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Lithuania |
61 |
| 1478 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Russian Federation |
49 |
| 1479 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
36 |
| 1480 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
62 |
| 1481 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
54 |
| 1482 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
74 |
| 1483 |
Apheresis |
Allogeneic |
NHL Non-Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
Poland |
49 |
| 1484 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
62 |
| 1485 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2025 |
Standard Therapy |
USA |
74 |
| 1486 |
Apheresis |
Allogeneic |
NHL Non-Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
Argentine |
57 |
| 1487 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
56 |
| 1488 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Belgium |
71 |
| 1489 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Spain |
59 |
| 1490 |
Apheresis |
Allogeneic |
Other Myelofibrosis/Myelosclerosis |
Hematology |
2025 |
Standard Therapy |
USA |
65 |
| 1491 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
14 |
| 1492 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Denmark |
57 |
| 1493 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
68 |
| 1494 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
51 |
| 1495 |
Apheresis |
Allogeneic |
Richter Transformation CDLBCC |
Hematology |
2025 |
Standard Therapy |
Germany |
68 |
| 1496 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia-MR |
Hematology |
2025 |
Standard Therapy |
Russian Federation |
16 |
| 1497 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
63 |
| 1498 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
66 |
| 1499 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
50 |
| 1500 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
38 |